Charles River Laboratories International, Inc. (CRL) Given New $130.00 Price Target at Jefferies Group LLC

Charles River Laboratories International, Inc. (NYSE:CRL) had its target price increased by Jefferies Group LLC from $120.00 to $130.00 in a research note released on Monday. Jefferies Group LLC currently has a buy rating on the medical research company’s stock.

Other analysts have also recently issued reports about the company. Robert W. Baird reiterated a buy rating and issued a $114.00 price objective on shares of Charles River Laboratories International in a research note on Friday, September 1st. Zacks Investment Research upgraded Charles River Laboratories International from a hold rating to a buy rating and set a $111.00 price objective on the stock in a research note on Wednesday, July 12th. BidaskClub cut Charles River Laboratories International from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Barclays PLC reiterated a hold rating and issued a $102.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Finally, Citigroup Inc. reiterated a neutral rating and issued a $104.00 price objective (up from $91.00) on shares of Charles River Laboratories International in a research note on Wednesday, June 28th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $100.50.

Shares of Charles River Laboratories International (CRL) opened at 110.46 on Monday. The company has a market capitalization of $5.26 billion, a price-to-earnings ratio of 29.11 and a beta of 0.96. Charles River Laboratories International has a 52 week low of $67.20 and a 52 week high of $110.82. The company’s 50 day moving average price is $107.04 and its 200-day moving average price is $97.57.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million for the quarter, compared to analysts’ expectations of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period last year, the firm earned $1.20 earnings per share. Analysts anticipate that Charles River Laboratories International will post $5.10 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2017/10/10/charles-river-laboratories-international-inc-crl-given-new-130-00-price-target-at-jefferies-group-llc.html.

In related news, insider Davide Molho sold 6,165 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Ross Smith sold 2,552 shares of the stock in a transaction on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the transaction, the insider now directly owns 11,671 shares in the company, valued at approximately $783,124.10. The disclosure for this sale can be found here. Insiders sold 22,529 shares of company stock worth $2,278,496 in the last three months. 2.20% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of CRL. UBS Asset Management Americas Inc. increased its holdings in Charles River Laboratories International by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 89,008 shares of the medical research company’s stock valued at $8,006,000 after buying an additional 228 shares during the last quarter. Schroder Investment Management Group increased its holdings in Charles River Laboratories International by 28.5% in the first quarter. Schroder Investment Management Group now owns 17,128 shares of the medical research company’s stock valued at $1,535,000 after buying an additional 3,804 shares during the last quarter. OppenheimerFunds Inc. increased its holdings in Charles River Laboratories International by 9.1% in the first quarter. OppenheimerFunds Inc. now owns 4,713 shares of the medical research company’s stock valued at $424,000 after buying an additional 394 shares during the last quarter. FMR LLC increased its holdings in Charles River Laboratories International by 39.7% in the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after buying an additional 707,612 shares during the last quarter. Finally, Advantus Capital Management Inc increased its holdings in Charles River Laboratories International by 3.1% in the first quarter. Advan

Other analysts have also recently issued reports about the company. Robert W. Baird reiterated a buy rating and issued a $114.00 price objective on shares of Charles River Laboratories International in a research note on Friday, September 1st. Zacks Investment Research upgraded Charles River Laboratories International from a hold rating to a buy rating and set a $111.00 price objective on the stock in a research note on Wednesday, July 12th. BidaskClub cut Charles River Laboratories International from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Barclays PLC reiterated a hold rating and issued a $102.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Finally, Citigroup Inc. reiterated a neutral rating and issued a $104.00 price objective (up from $91.00) on shares of Charles River Laboratories International in a research note on Wednesday, June 28th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $100.50.

Shares of Charles River Laboratories International (CRL) opened at 110.46 on Monday. The company has a market capitalization of $5.26 billion, a price-to-earnings ratio of 29.11 and a beta of 0.96. Charles River Laboratories International has a 52 week low of $67.20 and a 52 week high of $110.82. The company’s 50 day moving average price is $107.04 and its 200-day moving average price is $97.57.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million for the quarter, compared to analysts’ expectations of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period last year, the firm earned $1.20 earnings per share. Analysts anticipate that Charles River Laboratories International will post $5.10 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2017/10/10/charles-river-laboratories-international-inc-crl-given-new-130-00-price-target-at-jefferies-group-llc.html.

In related news, insider Davide Molho sold 6,165 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Ross Smith sold 2,552 shares of the stock in a transaction on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the transaction, the insider now directly owns 11,671 shares in the company, valued at approximately $783,124.10. The disclosure for this sale can be found here. Insiders sold 22,529 shares of company stock worth $2,278,496 in the last three months. 2.20% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of CRL. UBS Asset Management Americas Inc. increased its holdings in Charles River Laboratories International by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 89,008 shares of the medical research company’s stock valued at $8,006,000 after buying an additional 228 shares during the last quarter. Schroder Investment Management Group increased its holdings in Charles River Laboratories International by 28.5% in the first quarter. Schroder Investment Management Group now owns 17,128 shares of the medical research company’s stock valued at $1,535,000 after buying an additional 3,804 shares during the last quarter. OppenheimerFunds Inc. increased its holdings in Charles River Laboratories International by 9.1% in the first quarter. OppenheimerFunds Inc. now owns 4,713 shares of the medical research company’s stock valued at $424,000 after buying an additional 394 shares during the last quarter. FMR LLC increased its holdings in Charles River Laboratories International by 39.7% in the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after buying an additional 707,612 shares during the last quarter. Finally, Advantus Capital Management Inc increased its holdings in Charles River Laboratories International by 3.1% in the first quarter. Advantus Capital Management Inc now owns 6,065 shares of the medical research company’s stock valued at $546,000 after buying an additional 183 shares during the last quarter. 95.38% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply